Alexandria Real Estate Equities, Inc. Stock Price

Alexandria Real Estate Equities owns lab and office buildings used by life science companies, but empty space is rising and the company just cut its payout to save cash. The flip side is that the shares trade at a steep discount to what its properties and projects could be worth if leasing and asset sales start to stabilize.Read more

Alexandria Real Estate Equities sits in the middle of the life-sciences boom, but higher borrowing costs and slower lab leasing could make its returns far less predictable. See why heavy reliance on a few biotech hotspots and changing work patterns might keep empty space around longer—even as top-tier tenants and prime locations offer real support.Read more

Alexandria bets that top life-science clusters will keep needing purpose-built lab space, with big campus projects and long leases helping keep buildings full and cash flows steady. But higher borrowing costs, slower hiring by biotech tenants, and new competing lab supply in key cities could limit growth for longer than many expect.Read more

Alexandria owns hard-to-replace lab buildings in top research hubs, and long leases with well-known tenants could keep its rental income resilient over time even as the market stays choppy. But weaker biotech funding and slower deal-making are already showing up in leasing and occupancy, raising the question of whether today’s headwinds are temporary or longer-lasting.Read more